SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
News|Videos|September 23, 2026
An Uncharted Path: How Clinicians are Implementing Artificial Intelligence Across Cardiology
Fact checked by: Ryan Livingston
As AI continues to evolve at a breakneck pace, catch up on some of the ways it’s already been implemented in cardiovascular care.
Advertisement
Advertisement
Artificial intelligence (AI) is a burgeoning industry, evolving in practically every direction as it continues to develop. AI-based algorithms are being implemented in countless fields, medicine not least among them.
Related to this article
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
Iliyan D. Iliev, PhD, discusses how fluconazole targets gut Candida to improve disease activity in IBD.
Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.
Advertisement
Advertisement